Fennec Pharma Q4 Loss From Operations Widens - Quick Facts

(RTTNews) - Fennec Pharmaceuticals Inc. (FRX.TO) reported a fourth-quarter net loss from operations of $0.8 million which excludes a $2.2 million non-cash gain on derivatives for the fourth quarter ended December 31, 2014, compared to a net loss from operations of $0.4 million excluding the non-cash gain of $1.5 million in the same period 2013. Fourth-quarter net income was $1.39 million or $0.14 per basic share, compared to $1.11 million or $0.12 per share, prior year.

The company said the increase in the net loss from operations excluding the non-cash impact of derivatives is primarily due to an increase in general and administrative non-cash expenses associated with equity based compensation.

Research and development expenses totaled $0.2 million, compared to a $0.1 million in the same period in 2013.